Ra Pharmaceuticals Inc.’s successful top-line Phase IIb data with complement 5 (C5) inhibitor zilucoplan in generalized myasthenia gravis (gMG), unveiled on Dec. 10, gives the biotech an opportunity toward blockbuster sales with a self-administered therapy that offers several points of differentiation compared to Alexion Pharmaceuticals Inc.’s Soliris (eculizumab).
One of the highest-priced drugs in the world, Soliris became the only drug approved specifically to treat myasthenia gravis (MG)...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)